Search

Your search keyword '"Smit, Willem M."' showing total 3 results
Start Over Author "Smit, Willem M." Database OAIster
3 results on '"Smit, Willem M."'

1. Treatment patterns and clinical outcomes of asciminib in a real-world multiresistant chronic myeloid leukemia patient population

Author

Kockerols, Camille C.B., Janssen, Jeroen J.W.M., Blijlevens, Nicole M.A., Klein, Saskia K., van Hussen-Daenen, Laura G.M., van Gorkom, Gwendolyn G.Y., Smit, Willem M., van Balen, Peter, Biemond, Bart J., Cruijsen, Marjan J., Corsten, Maarten F., te Boekhorst, Peter A.W., Koene, Harry R., van Sluis, Geerte L., Cornelissen, Jan J., Westerweel, Peter E., Kockerols, Camille C.B., Janssen, Jeroen J.W.M., Blijlevens, Nicole M.A., Klein, Saskia K., van Hussen-Daenen, Laura G.M., van Gorkom, Gwendolyn G.Y., Smit, Willem M., van Balen, Peter, Biemond, Bart J., Cruijsen, Marjan J., Corsten, Maarten F., te Boekhorst, Peter A.W., Koene, Harry R., van Sluis, Geerte L., Cornelissen, Jan J., and Westerweel, Peter E.

Published
2023

2. Treatment patterns and clinical outcomes of asciminib in a real-world multi-resistant chronic myeloid leukemia patient population

Author

MS Hematologie, Externen Hematologie, Kockerols, Camille C B, Janssen, Jeroen J W M, Blijlevens, Nicole M A, Klein, Saskia K, Van Hussen-Daenen, Laura G M, Van Gorkom, Gwendolyn G Y, Smit, Willem M, Van Balen, Peter, Biemond, Bart J, Cruijsen, Marjan J, Corsten, Maarten F, Te Boekhorst, Peter A W, Koene, Harry R, Van Sluis, Geerte L, Cornelissen, Jan J, Westerweel, Peter E, MS Hematologie, Externen Hematologie, Kockerols, Camille C B, Janssen, Jeroen J W M, Blijlevens, Nicole M A, Klein, Saskia K, Van Hussen-Daenen, Laura G M, Van Gorkom, Gwendolyn G Y, Smit, Willem M, Van Balen, Peter, Biemond, Bart J, Cruijsen, Marjan J, Corsten, Maarten F, Te Boekhorst, Peter A W, Koene, Harry R, Van Sluis, Geerte L, Cornelissen, Jan J, and Westerweel, Peter E

Published
2023

3. Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia.

Author

UCL - MD/MINT - Département de médecine interne, UCL - (SLuc) Service d'hématologie, Deenik, Wendy, van der Holt, Bronno, Verhoef, Gregor E G, Smit, Willem M, Kersten, Marie J, Kluin-Nelemans, Hanneke C, Verdonck, Leo F., Ferrant, Augustin, Schattenberg, Anton V M B, Janssen, Jeroen J W M, Sonneveld, Pieter, van Marwijk Kooy, Marinus, Wittebol, Shulamit, Willemze, Roelof, Wijermans, Pierre W, Westveer, Petra H M, Beverloo, H Berna, Valk, Peter, Löwenberg, Bob, Ossenkoppele, Gert J, Cornelissen, Jan J, UCL - MD/MINT - Département de médecine interne, UCL - (SLuc) Service d'hématologie, Deenik, Wendy, van der Holt, Bronno, Verhoef, Gregor E G, Smit, Willem M, Kersten, Marie J, Kluin-Nelemans, Hanneke C, Verdonck, Leo F., Ferrant, Augustin, Schattenberg, Anton V M B, Janssen, Jeroen J W M, Sonneveld, Pieter, van Marwijk Kooy, Marinus, Wittebol, Shulamit, Willemze, Roelof, Wijermans, Pierre W, Westveer, Petra H M, Beverloo, H Berna, Valk, Peter, Löwenberg, Bob, Ossenkoppele, Gert J, and Cornelissen, Jan J

Abstract

The HOVON cooperative study group performed a feasibility study of escalated imatinib and intravenous cytarabine in 165 patients with early chronic-phase chronic myeloid leukemia (CML). Patients received 2 cycles of intravenous cytarabine (200 mg/m(2) or 1000 mg/m(2) days 1-7) in conjunction with imatinib (200 mg, 400 mg, 600 mg, or 800 mg), according to predefined, successive dose levels. All dose levels proved feasible. Seven dose-limiting toxicities (DLTs) were observed in 302 cycles of chemotherapy, which were caused by streptococcal bacteremia in 5 cases. Intermediate-dose cytarabine (1000 mg/m(2)) prolonged time to neutrophil recovery and platelet recovery compared with a standard dose (200 mg/m(2)). High-dose imatinib (600 mg or 800 mg) extended the time to platelet recovery compared with a standard dose (400 mg). More infectious complications common toxicity criteria (CTC) grade 3 or 4 were observed after intermediate-dose cytarabine compared with a standard-dose of cytarabine. Early response data after combination therapy included a complete cytogenetic response in 48% and a major molecular response in 30% of patients, which increased to 46% major molecular responses at 1 year, including 13% complete molecular responses. We conclude that combination therapy of escalating dosages of imatinib and cytarabine is feasible. This study was registered at www.kankerbestrijding.nl as no. CKTO-2001-03.

Published
2008

Catalog

Books, media, physical & digital resources
See catalog results